Royalty Pharma is a diversified pharma-royalty cash machine — it owns synthetic and acquired royalty streams on 35+ blockbuster drugs (Trikafta, Tremfya, Evrysdi, Trodelvy, Xtandi). No labs, no factories, just contractual cash flow at an ~84% operating margin. Four straight beats, an active $3.0B buyback (≈$1.3B used, $1.7B remaining), and a very low 0.42 beta make it a rare quality-value-dividend triple. The kicker: at $54.87 it sits only ~1.3% above a rising EMA20 — the most actionable name in the set, not an extended chase.RP Q1 2026· mai 2026
Royalty Pharma is the largest buyer of biopharmaceutical royalties in the world. Instead of discovering or manufacturing drugs, it buys the royalty streams attached to blockbuster therapies — either from inventors and academic institutions or via "synthetic" royalties funded directly to developers. The result is a diversified, asset-light portfolio of royalties on 35+ commercial products plus 19 development-stage candidates, spanning cystic fibrosis (Vertex's Trikafta/Alyftrek), immunology (J&J's Tremfya), neuroscience (Roche's Evrysdi, Biogen's Spinraza) and oncology (Gilead's Trodelvy, Pfizer/Astellas' Xtandi).RP IR· mai 2026
The economics are unusual and powerful: with almost no operating costs, the company converts royalty receipts into cash at an ~84% operating margin. Q1 2026 Royalty Receipts grew 13% to $887M, led by Tremfya, Voranigo and Evrysdi (partly offset by generic erosion on Promacta). The single risk that matters is capital deployment — growth depends on Royalty Pharma's ability to keep acquiring high-quality streams at attractive prices, and on the patent longevity of its top drugs.
| Metric | Value | Signal |
|---|---|---|
| Revenue (FY2025) | $2.38B | Royalty receipts +13% Q1 |
| Adj. EBITDA (Q1 2026) | $889M | ~$3.5B annualized |
| Gross Margin | ~95% | Royalty model |
| Operating Margin | ~84% | Exceptional |
| Net Margin (FY2025) | ~32% | $771M net income |
| Portfolio Cash Flow (FY2025) | $2.7B | Cash machine |
| 2026 Portfolio Receipts Guide | $3.325B – $3.45B | Raised at Q1; +3% to +8% royalties |
| Fwd P/E | 9.8x | Value |
| P/B | 3.53x | Fair (book $15.53) |
| PEG | 2.05 | Reasonable |
| Analyst Target (consensus) | $59 | Strong Buy |
This is the part that separates a quality compounder from a value trap. There is no equity-raise dilution — no active ATM, no S-3 equity offering, no convertibles, no toxic financing. Capital is being returned: in January 2025 the board authorized a $3.0B buyback, of which roughly $1.3B has been deployed and ~$1.7B remains as of 31 Mar 2026 — that first $1.23B tranche retired ~37.4M shares (~8.5% of the count), and weighted-average diluted shares actually fell ~4% year-over-year to ~557M in Q1 2026. The two real (but bounded) dilution vectors are: (1) the May 2025 internalization of the external manager (RP Management), a ~$1.1B deal funded mostly in ~24.5M RPRX shares (≈4% of the count) that vest over 5–9 years — a one-off, already-disclosed stock-funded acquisition, not a recurring equity tap; and (2) share-based compensation — ~$122M of SBC in Q1 2026, plus ~$716M of unrecognized comp (Class E interests + Employee EPAs). Even after both, the buyback wins: net of repurchases vs. SBC + manager vesting, the diluted share count is shrinking, not growing.RPRX 10-Q Q1 2026· mai 2026
No active ATM, no S-3 equity raise, no convertibles, no toxic financing. Capital is returned via an active $3.0B buyback ($1.7B remaining) plus a four-year rising dividend. Two bounded caveats: the May 2025 manager internalization was funded mostly in ~24.5M vesting shares (≈4%, a disclosed one-off), and ongoing share-based comp (~$122M/qtr, ~$716M unrecognized) — material but not the death-spiral kind. Net of buyback vs. both, the diluted share count actually fell ~4% YoY, so the float is shrinking, not flat.SEC EDGAR· 2026
| RSI (14) | 57.3 |
| EMA 20 | $54.17 |
| EMA 50 | $51.82 |
| EMA 200 | $44.52 |
| MACD | 1.090 |
| Signal | 1.240 |
| ATR (14) | $1.32 |
Textbook bullish stack: EMA20 ($54.17) > EMA50 ($51.82) > EMA200 ($44.52), all rising, confirming a clean uptrend that has carried RPRX from the mid-$20s. The key point for entry timing is that price sits only ~1.3% above the rising EMA20 — this is a name riding its trend line, not stretched far above it. RSI 57.3 is a healthy neutral-to-bullish reading with room to run before overbought. ATR is a tight $1.32 (~2.4% of price), so risk can be defined cleanly. MACD is marginally below its signal line, which simply reflects recent consolidation digesting the rally — a constructive base near support.Finviz· live
A diversified, cash-generative, low-beta royalty model with a clean balance-sheet narrative. The genuine risks are structural — drug concentration / patent cliffs, deal-pacing, and rate sensitivity of the royalty NPV — rather than dilution or solvency.
Three structural risks (concentration, deal pace, rates) are genuine but diluted across 35+ drug streams and offset by a fortress cash flow profile. There is no equity-raise dilution and no solvency risk (the only dilution vector is moderate share-based comp, partly offset by the active buyback), plus a very low 0.42 beta. This is about as low-drama as healthcare exposure gets — the reason it earns a defensive-diversifier role rather than a speculative one.RP Q1 2026· mai 2026
This is the rare A+ name you can buy at the live price rather than wait for a distant pullback. RPRX trades just above a rising EMA20 with a clean EMA20>50>200 stack, so the entry at $54.50 sits right on trend support. The stop at $51.60 is parked below the EMA50 ($51.82) — a structural break, not noise — for $2.90 of risk. TP1 at $59.00 maps to the consensus-high target cluster (Goldman $51, Citi $66, ~$59 consensus), giving $4.50 of reward and a recomputed R/R of 4.50 / 2.90 = 1.55, above the 1.5 threshold at an entry within 1% of spot. Quality value, defensive beta, and capital returned — you're paid to be patient via a 1.71% dividend while the thesis plays out.Targets / Yahoo· 2026
This analysis is provided for informational and educational purposes only. It does not constitute financial advice, investment recommendation, or solicitation to buy or sell any security.
Past performance is not indicative of future results. All investments involve risk, including the possible loss of principal. Always conduct your own research and consult a licensed financial advisor before making investment decisions.
Data sourced from DailyTickers Gateway, Yahoo Finance, SEC EDGAR, Royalty Pharma investor relations, and public market data. Accuracy is not guaranteed.